Tony Berberabe, MPH

Patients who underwent extended lymph node dissection during radical cystectomy compared with those who underwent standard lymph node dissection exhibited no benefit in disease-free survival or overall survival.

Although immune checkpoint inhibitors have become a cornerstone of therapy across cancer settings, their use in most breast cancer settings has fallen short.

Targeted therapies and immunotherapies across the ovarian, endometrial, and cervical cancers landscape play expanded roles, according to Ritu Salani, MD, MBA.

No differences in efficacy and safety were seen in a study cohort of 1325 patients undergoing frontline treatment with lenvatinib for unresectable hepatocellular carcinoma.

The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.

Druggable gene aberrations and predictive biomarkers has allowed for the use of next-generation sequencing technologies to grow.

Though osimertinib is the preferred frontline approach to treatment for those with non-small cell lung cancer with classic EGFR mutations, acquired resistance mechanisms invariably develop.

Findings from recent clinical research have firmly entrenched the use of neoadjuvant immune checkpoint blockade in the treatment of early-stage non-small cell lung cancer.

Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.

In locally advanced cervical cancer, the combination of neoadjuvant tislelizumab plus chemotherapy was demonstrated to be safe with encouraging antitumor activity.

Data from the phase 3 POSEIDON trial support the use of tremelimumab, durvalumab, and chemotherapy for patients with metastatic non–small cell lung cancer, including harder-to-treat subgroups, in the first-line.

Six CAR T-cell therapies have gained FDA approval across hematologic malignancy settings. These approvals have spurred further exploration for their use in solid tumors.

Circulating tumor DNA failed to indicate if patients with low-risk stage II colon cancer would benefit from adjuvant chemotherapy after surgery.

The sequencing of treatments for neuroendocrine tumors lacks robust clinical trials to serve as guideposts because of the heterogeneity of the tumors and their rare incidence.

The latest advances regarding local and systemic regulatory mechanisms of immune responses in cold and hot tumors will be an important topic explored during the 9th Annual School of Gastrointestinal Oncology.

Research is ongoing to identify biomarkers in hepatocellular carcinoma that are predictive in nature, according to Richard Kim, MD.

The landmark study, KEYNOTE-564, compared pembrolizumab vs placebo in patients with clear cell renal cell carcinoma who were at high risk for recurrence after nephrectomy.

Findings from the MOMENTUM study evaluating momelotinib demonstrated symptom, spleen, and anemia benefits in myelofibrosis compared with danazol in previously treated patients with anemia and intermediate- or high-risk myelofibrosis.

In a presentation during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow conference, Jessica Lin, MD, discussed the landscape of targeted therapies in driver mutations in non–small cell lung cancer.

New treatments, including luspatercept-aamt, have been added to the treatment algorithm of patients with low-risk myelodysplastic syndrome in 2020.

Molecular minimal residual disease assessed after chemotherapy induction can identify patients with NPM1-mutated acute monocytic leukemia.

Improvement in progression-free-survival was demonstrated across all relevant subgroups in patients with ER-positive/HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Significant findings from a number of trials in the lung cancer space will make their way into case reports.

Findings presented during the 2023 ESMO Annual Meeting have demonstrated a new combination of targeted therapies offering clinicians and patients renewed hope in this difficult to treat cancer type.

Findings from the EPCORE CLL-1 trial were presented by Arnon Kater, MD, PhD, during the 2023 International Workshop on CLL, held October 6 to 9, 2023, in Boston, Massachusetts.

AMG 193 had a promising safety profile and robust target engagement in a dose-escalating trial across tumor types.

At the recent European Society for Medical Oncology Congress 2023, a number of trials evaluated antibody-drug conjugates in non–small cell lung cancer.

In a subgroup analysis of the phase 3 EMBARK study, enzalutamide alone or with leuprolide acetate improved metastatic-free survival in men with high-risk prostate cancer following radiotherapy.

As a monotherapy, bispecific antibodies have demonstrated antitumor activity in heavily pretreated patients with B-cell and T-cell hematologic malignancies, but much work is needed to determine the optimal setting.

The role of risk stratification in treatment decisions for patients with newly diagnosed, transplant eligible multiple myeloma vs newly diagnosed, transplant ineligible multiple myeloma was explored by Natalie S. Callander, MD.